Key Takeaways:
- Windtree Therapeutics’ stock plummeted 77% after receiving a Nasdaq delisting notice for failing to meet the $1 bid price requirement.
- The biotech firm’s BNB treasury strategy briefly boosted its stock in July but has since led to over a 90% drop from its peak.
- Despite delisting, Windtree plans to continue financial disclosures while BNB hit a new all-time high at $876.26.
Windtree Therapeutics, a biotech firm that recently adopted a BNB-based treasury model, saw its stock plunge 77% after receiving a Nasdaq delisting notice.
According to a filing with the U.S. SEC, Windtree failed to meet the exchange’s minimum bid price requirement of $1 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
JUST IN: Nasdaq to delist BNB treasury’s Windtree Therapeutics ($WINT). pic.twitter.com/iP38m2LotY
— ChainDesk (@ChainDesk_) August 21, 2025
As a result, trading of Windtree’s stock (WINT) will be suspended starting Thursday.
Shares closed at $0.11, down sharply from $0.48 the previous day, and slipped further in after-hours trading.
The company’s stock had briefly rallied in mid-July following a $60 million BNB purchase agreement with Build and Build Corp., which included an option to expand up to $200 million.
Windtree also secured a $500 million equity line of credit and a separate $20 million BNB deal.
Despite these moves, the stock is now down more than 90% from its July 18 peak.
Despite the setback, CEO Jed Latkin confirmed that Windtree will continue its financial reporting obligations.
Other firms, such as Argo Blockchain, have regained Nasdaq listings after addressing compliance issues.
In contrast, BNB surged 5.6% to $876.26, marking a new all-time high amid a broader market rebound.